leisure time -WSS

leisure time

author：focus 2025-09-28 13:42:25 - browse：487

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Lupron, used to halt puberty in children, may cause lasting health problems

WSS

Scientists grapple with ethics of stem cell research

After a decade, new Gardasil ad campaign gets it (mostly) right

After a decade, new Gardasil ad campaign gets it (mostly) right

'Screen and refer' systems are hurting patients

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

focus

leisure time

focus

Heart attack and stroke risk calculators need revising

Hormonal contraceptives don’t actually treat endometriosis

After affirmative action ruling, medical educators look to 'holistic review'

Delta passengers in Vegas fall sick while waiting on flight in triple

Medical records are filled with copy

What affirmative action's end means to a medical student

In Memoriam: Notable people who died in 2023

Use doctors trained outside the U.S. to ease the physician shortage

BioMarin wins approval for gene therapy to treat hemophilia A

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

entertainment

Telehealth startups are trying to fill the menopause care vacuum

A letter from the executive editor: The 2023 STATUS List

Extensive review finds private equity owners jack up cost of care

Mystery swirls around US soldier who entered North Korea days ago, officials say

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Sanders wants to replace patents with prizes for drug inventions

Wikipedia

hotspot

leisure time

leisure time